Dexamethasone Moxifloxacin — Class II drug recall D-0249-2026
Ongoing recall by Imprimis NJOF, LLC, reported 2026-01-14, distributed nationwide. Presence of particulate matter - Glass like particles.
| Recall number | D-0249-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Imprimis NJOF, LLC, Ledgewood, NJ, United States |
| Recall initiated | 2025-12-18 |
| Classified | 2026-01-02 |
| Reported by FDA | 2026-01-14 |
| Distributed | Nationwide (US) |
| Reason classes | foreign material, specification failure |
| Lot numbers | 25AUG003, 25MAY051 |
| Expiration dates | 2026-06-26, 2026-08-07 |
Product
Dexamethasone Moxifloxacin, 1 mg/mL and 5 mg/mL, 1 mL Intraocular Injection, Rx only, Imprimis NJOF, LLC, Ledgewood, NJ 07852, NDC 71384-512-0.1
Reason for recall
Presence of particulate matter - Glass like particles.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0249-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.